<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Kintor Pharmaceutical Ltd — News on 6ix</title>
    <link>https://6ix.com/company/kintor-pharmaceutical-ltd</link>
    <description>Latest news and press releases for Kintor Pharmaceutical Ltd on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Fri, 25 Jul 2025 23:30:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/kintor-pharmaceutical-ltd" rel="self" type="application/rss+xml" />
    <item>
      <title>Phase II Stage Of Pivotal Clinical Trial Of KX-826 Tincture 1.0% For The Treatment Of Male Adult Aga In China Reached Primary Endpoint</title>
      <link>https://6ix.com/company/kintor-pharmaceutical-ltd/news/phase-ii-stage-of-pivotal-clinical-trial-of-kx-826-tincture-10percent-for-the-treatment-of-male-adult-aga-in-china-reached-primary-endpoint</link>
      <guid isPermaLink="true">https://6ix.com/company/kintor-pharmaceutical-ltd/news/phase-ii-stage-of-pivotal-clinical-trial-of-kx-826-tincture-10percent-for-the-treatment-of-male-adult-aga-in-china-reached-primary-endpoint</guid>
      <pubDate>Fri, 25 Jul 2025 23:30:00 GMT</pubDate>
      <description>The Kintor Pharmaceutical Limited (the &quot;Company&quot;) is pleased to announce that the Phase II Stage of the Pivotal Clinical Trial of its in-house developed and potential first-in-class KX-826 tincture 1.0% for the treatment of AGA has obtained top-line results. Results indicated that the Phase II Stage has reached its primary endpoint with statistically significant and clinically meaningful outcomes, demonstrating excellent efficacy and safety. Analysis results of the 90 patients enrolled in the Ph</description>
    </item>
  </channel>
</rss>